CE Disclosures and Faculty Information

• TARGET AUDIENCE
  
  This activity is intended for medical oncologists, breast surgeons and other healthcare providers involved in the treatment of breast cancer.
  
  OVERVIEW OF ACTIVITY
  
  Breast cancer remains the most frequently diagnosed cancer in women, and it is estimated that 226,870 new cases and approximately 40,000 attributable deaths will occur in the United States in 2012 alone. Advances in screening and prevention have resulted in a steady down-stage migration at the time of disease presentation, such that only 5% of women have identifiable distant metastases at primary diagnosis. Consequently, the number of individuals living with breast cancer has increased substantially, as has the population “at risk” for recurrent disease.
  
  The current clinical management of breast cancer is multidisciplinary and includes surgical resection of local disease with or without radiation therapy and the treatment of systemic disease (micro- or macroscopic) with cytotoxic chemotherapy, endocrine therapy, biologic therapy or combinations of these agents. In addition, diagnosis may now include description of a molecular subtype, derived from either gene microarray analysis or simply immunohistochemical cellular receptor expression profiles. By providing access to the latest research developments and expert perspectives, these proceedings from a case-based CME symposium held at the 2012 ASCO Annual Meeting aims to assist medical oncologists, breast surgeons and other healthcare providers as they attempt to formulate optimal disease management strategies in the face of a constantly evolving body of knowledge.
  
  LEARNING OBJECTIVES

  • Employ case-based learning to individualize the treatment of localized and advanced breast cancer.
  • Use currently available tissue-based genomic assays to assist with therapeutic decision-making in the management of node-negative and node-positive early breast cancer in addition to noninvasive breast cancer.
  • Apply the results of recent clinical research when recommending HER2-directed therapy for patients with trastuzumab-naïve and previously exposed breast cancer.
  • Identify existing and emerging rational systemic treatments for patients with triple-negative breast cancer.
  • Develop an evidence-based algorithm for the treatment of advanced hormone receptor-positive breast cancer.
  • Recall the efficacy and safety of emerging compounds for patients with breast cancer and, when appropriate, integrate them into existing treatment algorithms.
  • Counsel appropriately selected patients with breast cancer about participation in ongoing clinical trials.

  ACCREDITATION STATEMENT
  
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  CME credit is no longer available for this issue
  
  CREDIT DESIGNATION STATEMENT
  
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  
  This CME activity consists of a video component. The participant should watch the video.
  
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Harold J Burstein, MD, PhD
  Associate Professor of Medicine
  Harvard Medical School
  Breast Oncology Center
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  No real or apparent conflicts of interest to disclose.
  
  Angelo Di Leo, MD, PhD
  Head of Sandro Pitigliani Medical Oncology Unit
  Department of Oncology
  Hospital of Prato
  Istituto Toscano Tumori
  Prato, Italy
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Genomic Health Inc, Roche Laboratories Inc, Sanofi.
  
  Ana Maria Gonzalez-Angulo, MD, MSc
  Associate Professor
  Department of Breast Medical Oncology
  Department of Systems Biology
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee: Bayer HealthCare Pharmaceuticals; Paid Research: Bristol-Myers Squibb Company, Celgene Corporation, Novartis Pharmaceuticals Corporation; PI on Trial: Genomic Health Inc.
  
  Mark D Pegram, MD
  Director, Breast Oncology Program
  Co-Director, Experimental Therapeutics Program
  Professor of Medicine
  Stanford University Medical Center
  Stanford, California
  
  Advisory Committee: Amgen Inc, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Millennium: The Takeda Oncology Company; Consulting Agreement: Genentech BioOncology; Data and Safety Monitoring Board: Pfizer Inc.
  
  Hope S Rugo, MD
  Professor of Medicine
  Director, Breast Oncology and Clinical Trials Education
  University of California, San Francisco
  Helen Diller Family Comprehensive Cancer Center
  San Francisco, California
  
  Paid Research: Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Pharmaceuticals.
  
  RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Eisai Inc, Genentech BioOncology and Genomic Health Inc.
  
  Hardware/Software Requirements:
  An Internet connection that is at least 28.8 Kbps
  A monitor set to 1280 x 1024 pixels or more
  Netscape 7.x or newer, Internet Explorer 5.x or newer, or Firefox
  Macromedia Flash plug-in 6.0 or greater
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Last review date: July 2012
  Expiration date: July 2013